Live· 124 releases in the last 30 days
Trial readouts, the day they publish.
Topline results, phase 3 outcomes, enrolment completions and study terminations. A readout moves a company before any analyst note exists, and the release is the only primary source.
Latest on this wire
Releases are matched on the headline, deduplicated, and exclude securities-litigation solicitations. Each links to the publisher's original.
What to watch for
Read what the release does NOT say. A topline that reports a secondary endpoint first, or omits the p-value, is telling you something the headline is not.
Frequently asked questions
- Is 'phase 3' matched loosely?
- No — it requires the trial noun. A gold mine's 'Phase 3 land programme' matched the loose version, which is why the term is anchored.
- Does this include regulators?
- Approvals and rejections come from the agencies themselves and appear alongside company readouts.
Monitoring clinical trials on the wire
Why the wire beats the news
By the time a story is written, the release it came from has been public for hours — and the ones nobody wrote about are never seen at all. Most of what crosses this topic is the second kind: a regulator's notice, a mid-size company's filing, a ministry statement in a language the wires do not translate. That is where the stories nobody else has come from.
How current this page is
This page refreshes hourly and shows the twelve most recent matching releases. The live feed updates continuously and reaches the whole archive, and alerts fire the moment a new release matches.
You are seeing 12 of 124.
The other 112 crossed the wire in the last 30 days on this topic alone — most of them never reached a news site. A release is only useful before everyone else has it, and this page is a day behind by design.
Watch this topic live →Free to start. No card. Cancel in one click.